Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxotemitide - Lytix Biopharma

Drug Profile

Ruxotemitide - Lytix Biopharma

Alternative Names: Cancer-vaccine-Lytix-Biopharma; LTX-315; Oncopore; VP-315; VP-LTX-315

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lytix Biopharma
  • Developer Lytix Biopharma; Verrica Pharmaceuticals
  • Class Adjuvants; Amides; Amines; Antineoplastics; Benzyl compounds; Butylamines; Immunotherapies; Indoles; Peptides
  • Mechanism of Action Cell membrane structure modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I/II Solid tumours
  • No development reported Carcinoma; Triple negative breast cancer

Most Recent Events

  • 31 Dec 2023 Lytix Biopharma files for patent protection with Patent Corporation Treaty (PCT) for Ruxotemitide (LTX 315)
  • 31 Dec 2023 Lytix Biopharma files an clinical trial application with the regulatory authorities in stage III-IV melanoma
  • 23 Oct 2023 Updated efficacy and safety data from the phase II ATLAS-IT-05 trial in Malignant melanoma released by Lytix Biopharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top